Table 2.
Efficacy results: MS relapses after 2 years of treatment
| Endpoint | Previously on placebo (n = 43) | Previously on natalizumab (n = 44) |
|---|---|---|
| Patients with relapse, n (%) | 14 (33) | 10 (23) |
| Patients with number of relapses, n (%) | ||
| 0a | 29 (67) | 34 (77) |
| 1 | 9 (21) | 8 (18) |
| 2 | 3 (7) | 2 (5) |
| 3 | 1 (2) | 0 (0) |
| ≥4 | 1 (2) | 0 (0) |
| Total relapses, n | 27 | 12 |
| Total patient-years | 85.6 | 86.3 |
| Unadjusted ARRb | 0.32 | 0.14 |
| Patient-based ARRc | 0.40 | 0.16 |
ARR annualized relapse rate, MS multiple sclerosis
aIncludes patients who withdrew from the study and did not experience a relapse prior to withdrawal
bTotal number of relapses during the study divided by the total number of patient-years in the study
cNumber of relapses for each patient divided by the number of years in the study for that patient